Semaglutide, sold under brands Ozempic, Wegovy and Rybelsus is a medication for chronic weight management used in conjunction with diet and exercise. When used in conjunction with lifestyle changes, this weight loss drug can be effective in helping patients lose excess weight. It comes in the form of a Semaglutide injection of 2.4 mg. It is manufactured by the Danish pharmaceutical company Novo Nordisk. Semaglutide is an under-the-skin, self-administered injectable prescription medicine for chronic weight management, used in addition to a reduced-calorie diet and increased exercise. It is for patients with either:
- A body mass index (BMI) of 30 kg/m2 or greater
- A BMI of 27 kg/m2 or greater with at least one weight-related ailment such as type 2 diabetes, hypertension, sleep apnea, or others.
Semaglutide is FDA approved for weight loss in obese or overweight patients with other weight-related conditions such as type 2 diabetes, high blood pressure, high cholesterol, or others.
Obesity is a chronic health issue that requires long-term management and is associated with severe health complications, including heart disease, diabetes, sleep apnea, asthma, hormonal concerns for women such as PCOS, arthritis, and certain types of cancer. Losing five to ten percent of body weight can bring impactful health benefits, such as:
•Reduced risk of cardiovascular disease
•Improved blood pressure, blood sugar, and cholesterol levels
On June 4, 2021, the U.S. Food and Drug Administration (FDA) approved Semaglutide for adults who suffer from obesity or are overweight. This is the first drug for chronic weight management that has been approved since 2014.
In combination with a reduced-calorie meal plan and increased physical activity, Semaglutide can be extremely effective in helping patients lose weight.
There are no reviews yet.